nafamostat has been researched along with lopinavir in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Akahoshi, T; Iwasaka, S; Maki, J; Nagasaki, Y; Nakashima, K; Shimono, N; Shono, Y; Taguchi, T; Tokuda, K; Yamamoto, Y | 1 |
| Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ | 1 |
| Bojkova, D; Ciesek, S; Cinatl, J; Claussen, C; Ellinger, B; Geisslinger, G; Gribbon, P; Keminer, O; Kuzikov, M; Reinshagen, J; Westhaus, S; Wolf, M; Zaliani, A | 1 |
3 review(s) available for nafamostat and lopinavir
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication | 2021 |
2 other study(ies) available for nafamostat and lopinavir
| Article | Year |
|---|---|
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Guanidines; Hemodiafiltration; Humans; Hydroxychloroquine; Japan; Lopinavir; Male; Pandemics; Pneumonia, Viral; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Esters; Guanidines; Humans; Lopinavir; Mefloquine; Papaverine; SARS-CoV-2 | 2021 |